Y-mAbs Therapeutics, Inc. announced that on April 25, 2024, Gérard Ber, Ph.D., notified the company that he would be resigning from the Board of Directors of the Company, with such resignation to be effective on June 10, 2024, the day before the date set for the Company?s 2024 annual meeting of stockholders. Dr. Ber?s resignation is not due to any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.73 USD | +5.91% | +3.75% | +86.66% |
Jun. 05 | Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer | CI |
Jun. 01 | Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.66% | 527M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024